A first-line treatment that’s FDA approved to treat your patients as young as 1 month
Multiple pediatric Indications from 1 month to 17 years old
- Short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis
- In infants 1 month to less than 1 year, NEXIUM is indicated for the short-term treatment (up to 6 weeks) of erosive esophagitis due to acid mediated gastroesophageal reflux disease (GERD)
- Short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in children 1 year and older
The safety and effectiveness of NEXIUM for patients younger than 1 month has not been established.